Anti-psoriatic drug anthralin activates transcription factor NF-κB in murine keratinocytes

Journal of Immunology

Volumn 156, Issue 11, 1996, Pages 4514-4519

  Schmidt, Kerstin N ^a   Podda, Maurizio ^b   Packer, Lester ^b   Baeuerle, Patrick A ^a,c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; DITHRANOL; GLUTATHIONE PEROXIDASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THIOREDOXIN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOOXIDATION; CELL PROLIFERATION; ENZYME ACTIVITY; HYPERKERATOSIS; IMMUNE RESPONSE; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS VULGARIS;

ADMINISTRATION, TOPICAL; ANIMALS; ANTHRALIN; ANTI-INFLAMMATORY AGENTS; CATALASE; CELL LINE; HUMANS; HYDROGEN PEROXIDE; KERATINOCYTES; MICE; NF-KAPPA B; PSORIASIS; REACTIVE OXYGEN SPECIES; SECOND MESSENGER SYSTEMS; SUPEROXIDE DISMUTASE;

EID: 0029931241     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Rogers, S., J. Marks, S. Shuster, et al. 1979. Comparison of photochemotherapy with dithranol in the treatment of chronic plaque psoriasis. Lancet 1:455.
2. Kemény, L., T. Ruzicka, and O. Braun-Falco. 1990. Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol 3:1.
3. Sa E Melo, T., L. Dubertret, P. Prognon, A. Gond, G. Mahuzier, and R. Santus. 1983. Physiochemical properties and stability of anthralin in model systems and human skin. J. Invest. Dematol. 84:1.
4. Reichert, U., Y. Jaques, M. Grangeret, and R. Schmidt. 1985. Antirespiratory and antiproliferative activity of anthralin in cultured human keratinocytes. J. Invest. Dermatol. 84:130.
5. Krebs, A., and H. Schaltegger. 1969. Untersuchungen zur Strukturspezifität der Psoriasisheilmittel Chrysarobin und Dithranol. Hautarzt 20:204.
6. Mustakallio, K. K., J. Martinmaa, R. Vilvala, and J. Halmekoski. 1984. Free radicals and the treatment of psoriasis with special reference to dithranol. Med. Biol. 62:155.
7. Bruce, J. M., C. W. Kerr, and J. F. Dodd. 1987. Formation of superoxide during the auto-oxidation of anthralin. J. Chem. Soc. Faraday Trans. 1:85.
8. Martinmaa, J., L. Vanhala, and K. K. Mustakallio. 1978. Free radical intermediates produced by autooxidation of 1,8-dihydroxy-9-anthrone (dithranol) in pyridine. Experientia 34:871.
9. Martinmaa, J., J. Juselius, and K. K. Mustakallio. 1982. Free radicals by autoxidation of anthralin and its 10-acyl analogues. Br. J. Dermatol. 105:52.
10. Müller, K., W. Wiegrebe, and M. Younes. 1987. Dithranol, active oxygen species and lipid peroxidation in vivo. Arch. Pharm. Ber. Dtsch. Pharm. Ges. 320:59.
11. Hayden, P. J., K. E. Free, and C. F. Chignell. 1994. Structure-activity relationships for the formation of secondary radicals and inhibition of keratinocyte proliferation by 9-anthrones. Mol. Pharmacol. 46:186.
12. Schreck, R., and P. A. Baeuerle. 1991. A role for oxygen radicals as second messengers. Trends Cell Biol. 1:39.
13. Meyer, M., R. Schreck, J. M. Müller, and P. A. Baeuerle. 1994. Redox control of gene expression by eukaryotic transcription factors NF-κB, AP-1 and SRF/TCF. In Oxidative Stress, Cell Activation and Viral Infection. C Pasquier, ed. Birkhäuser Verlag, Basel, p. 217-235.
14. Grilli, M., J. J.-L. Chin, and M. J. Lenardo. 1993. NF-κB and rel: participants in a multiform transcriptional regulatory system. Int. Rev. Cytol. 143:1.
15. Grimm, S., and P. A. Baeuerle. 1993. The inducible transcription factor NF-kappa B: structure-function relationship of its protein subunits. Biochem. J. 290: 297.
16. Nolan, G. P., and D. Baltimore. 1992. The inhibitory ankyrin and activator Rel proteins. Curr. Opin. Genet. Dev. 2:211.
17. Beg, A. A., T. S. Finco, P. V. Nantermet, and A. S. Baldwin, Jr. 1993. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IκB-α: a mechanism for NF-κB activation. Mol. Cell. Biol. 13:3301.
18. Gilmore, T. D., and P. J. Morin. 1993. The IκB proteins: members of a multi-functional family. Trends Genet. 9:427.
19. Baeuerle, P. A., and T. Henkel. 1994. Function and Activation of NF-κB in the immune system. Annu. Rev. Immunol. 12:141.
20. Siebenlist, U., and G. Franzoso. 1995. NF-κB: a mediator of pathogen and stress responses. In Inducible Gene Expression. P. A. Baeuerle, ed. Birkhäuser, Boston.
21. Schreck, R., K. Albermann, and P. A. Baeuerle. 1992. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Rad. Res. Commun. 17:221.
22. Schreck, R., R. Grassmann, B. Fleckenstein, and P. A. Baeuerle. 1992. Antioxidants selectively suppress activation of NF-kappa B by human T-cell leukemia virus type I Tax protein. J. Virol. 66:6288.
23. Schreck, R., B. Meier, D. N. Mannel, W. Droge, and P. A. Baeuerle. 1992. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J. Exp. Med. 175:1181.
24. Suzuki, N., W. Peter, T. Ciesiolka, P. Gruss, and H. R. Scholer. 1993. Mouse Oct-1 contains a composite homeodomain of human Oct-1 and Oct-2. Nucleic Acids Res. 21:245.
25. Schenk, H., M. Klein, W. Erdbrügger, W. Dröge, and K. Schulze-Osthoff. 1994. Distinct effects of thioredoxin and other antioxidants on the activation of NF-κB and AP-1. Proc. Natl. Acad. Sci. USA 91:1672.
26. Schmidt, K. N., P. Amstad, P. Cerutti, and P. A. Baeuerle. 1995. The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-κB. Chem. Biol. 2:13.
27. Schreck, R., P. Rieber, and P. A. Baeuerle. 1991. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 10:2247.
28. 2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 12:2005.
29. Chen, Z., J. Hagler, V. J. Palomabella, F. Melandri, D. Scherer, D. Ballard, and T. Maniatis. 1995. Signal-induced site-specific phosphorylation targets IκB-α to the ubiquitin-proteasome pathway. Genes Dev. 9:1586.
30. Traenckner, E. B.-M., H. L. Pahl, T. Henkel, K. N. Schmidt, S. Wilk, and P. A. Baeuerle. 1995. Phosphorylation of human IκB-α on serine 32 and 36 controls IκB-α proteolysis and NF-κB activation in response to diverse stimuli. EMBO J. 14:2876.
31. Amstad, P., A. Peskin, G. Shah, M. E. Mirault, R. Moret, I. Zbinden, and P. Cerutti. 1991. The balance between Cu,Zn-superoxide dismutase and catalase affects the sensitivity of mouse epidermal cells to oxidative stress. Biochemistry 30:9305.
32. Amstad, P. A., G. Krupitza, and P. A. Cerutti. 1993. Mechanism of c-fos induction by active oxygen. Cancer Res. 52:3952.
33. Korner, M., A. Rattner, F. Mauxion, R. Sen, and Y. Citri. 1989. A brain-specific transcription activator. Neuron 3:563.
34. 2+ dependence, and differential half-site recognition. J. Biol. Chem. 266:252.
35. Elias, A. N., H. M. Goodman, and M. K. Rohan. 1993. Serum ICAM-1 concentrations in patients with psoriasis treated with antithyroid thiouracilenes. Clin. Exp. Dermatol. 18:526.
36. Elias, A. N., H. M. Goodman, and M. K. Rohan. 1993. Effect of propylthiouracil and methimazole on serum levels of interleukin-2 receptors in patients with psoriasis. Int. J. Dermatol. 32:537.
37. Elias, A. N., H. M. Goodman, M. K. Rohan, K. Alpern, and R. J. Barr. 1993. Methimazole (2-mercapto 1-methylimidazole) in psoriasis: results of an open trial. Dermatology 187:26.
38. Christophers, E. R., and G. C. Krueger. 1987. Psoriasis. In Dermatology in General Medicine. T. R. Fitzpatrick, et al., eds. McGraw-Hill, New York, pp. 461-491.
39. Mustakallio, K. K. 1988. Anthralin and related compounds: past, present and future. In Psoriasis, Proceedings of the Fourth International Symposium. Elsevier, New York, pp. 000-000.
40. Unna, P. G. 1916. Cignolin als Heilmittel der Psoriasis. Dermatol. Wochenschr. 62:116.
41. Joshi, P. C., and M. A. Pathak. 1984. The role of active oxygen induced by crude coal tar and its ingredients used in photochemotherapy of skin diseases. J. Invest. Dermatol. 82:67.
42. Müller, K., E. Eibler, K. K. Mayer, et al. 1986. Dithranol, singlet oxygen and unsaturated fatty acids. Arch. Pharm. Ber. Dtsch. Pharm. Ges. 319:2.
43. Müller, K. 1988. Active oxygen species and structure specificity of antipsoriatic anthrones. Arch. Pharm. Ber. Dtsch. Pharm. Ges. 321:385.
44. Finnen, M. J., C. M. Lawrence, and S. Shuster. 1984. Inhibition of dithranol inflammation by free radical scavengers. Lancet 2:1129.
45. Suzuki, Y. J., and L. Packer. 1993. Inhibition of NF-κB activation by vitamin E derivatives. Biochem. Biaphys. Res. Commun. 193:277.
46. Paramsothy, Y., C. M. Lawrence, and S. Shuster. 1986. Anthralin inflammation: lack of effect of topical thiocarbamide drugs. Br. J. Dermatol. 115:251.
47. Solanki, V., R. S. Rana, and T. J. Slaga. 1981. Diminution of mouse epidermal superoxide dismutase and catalase activities by tumor promoters. Carcinogenesis 2:1141.
48. Morlière, P., L. Dubertret, T. Se E Melo, C. Salet, M. Fosse, and R. Santus. 1985. The effect of anthralin (dithranol) on mitochondria. Br. J. Dermatol. 112:509.
49. Raab, W., and F. Patermann. 1966. Die Wirkung externer Antipsoriatika auf die Zellatmung. Arch. Klin. Exp. Dermatol. 226:144.
50. Swanbeck, G., and P. Lundquist. 1972. Ultrastructural changes of mitochondria in dithranol-treated psoriatic epidermis. Acta Derm. Venerol. 52:94.
51. Schubert, C., and E. Christophers. 1985. Ultrastructural changes in cutaneous infiltrates after dithranol treatment of psoriasis. J. Invest. Dermatol. 84:450.
52. Zetterberg, G. 1981. Effects of anthralin on mitochondrial and nuclear functions in yeast cells. Br. J. Dermatol. 105(Suppl. 20):39.
53. Schulze-Osthoff, K., A. C. Bakker, B. Vanhaesebroeck, R. Beyaert, W. A. Jacobs, and W. Fiers. 1992. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions: evidences for the involvement of mitochondrial radical generation. J. Biol. Chem. 267:5317.
54. Schulze-Osthoff, K., R. Beyaert, V. Vandevoorde, G. Haegeman, and W. Fiers. 1993. Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. EMBO J. 12:3095.
55. Fuchs, J., W. H. Nitschmann, and L. Packer. 1990. The antipsoriatic compound anthralin influences bioenergetic parameters and redox properties of energy transducing membranes. J. Invest. Dermatol. 94:71.
56. Lowe, N. J., and J. Breeding. 1981. Anthralin, different concentration effects on epidermal cell DNA synthesis rates in mice and clinical responses in human psoriasis. Arch. Dermatol. 117:698.
57. Fisher, L. B., and N. I. Maibach. 1975. The effects of anthralin and its derivatives on epidermal cell kinetics. Invest. Dermatol. 64:338.
58. Cavey, D., J.-C. Caron, and B. Shroot. 1981. Anthralin: chemical instability and glucose-6-phosphate dehydrogenase inhibition. J. Pharm. Sci. 71:980.
59. Lowe, N. J., R. Kaplan, and J. Breeding. 1982. Etretinate treatment for psoriasis inhibits epidermal ornithine decarbosylase. J. Am. Acad. Dermatol. 6:697.
60. Bedford, C. J., J. M. Young, and B. M. Wagner. 1983. Anthralin inhibition of mouse epidermal arachidonic acid lipooxygenase in vitro. J. Invest. Dermatol. 81:566.
61. Tucker, W. F. G., S. MacNeil, R. A. Dawson, S. Tomlinson, and S. S. Bleehen. 1986. An investigation of the ability of antipsoriatic drugs to inhibit calmodulin activity: a possible mode of action of dithranol (anthralin). J. Invest. Dermatol. 87:232.
62. Ternowitz, T. 1987. The enhances monocyte and neutrophil chemotaxis in psoriasis is normalized after treatment with psoralens plus ultraviolet A and anthralin. J. Am. Acad. Dermatol. 16:1169.
63. Anderson, R., P. Lukey, U. Dippenaar, H. A. Eftycrtis, G. H. Findlay, M. W. Wooten, and A. E. Nel. 1987. Dithranol mediates pro-oxidative inhibition of polymorphonuclear leukocyte migration and lymphocyte proliferation. Br. J. Dermatol. 117:405.
64. Schröder, J.-M., U. Kosfeld, and E. Christophers. 1985. Multifunctional inhibition by anthralin in nonstimulated and chemotactic factor stimulated human neutrophils. J. Invest. Dermatol 85:30.
65. Hodgeson, C., and E. Mell. 1970. Clinical comparison between triacetoxyanthracene and dithranol pastes in the treatment of chronic psoriasis. Br. J. Dermatol. 83:397.
66. Raab, W. 1976. Dithranol (anthralin) versus triacetoxyanthracene. Br. J. Dermatol. 95:193.
67. Kingston, R., and R. Marks. 1983. Irritant reactions to dithranol in normal subjects and psoriatic subjects. Br. J. Dermatol. 108:307.
68. Kemény, L., M. Csatò, J. Nyiràdi, M. Gabor, and A. Dobozy. 1989. Untersuchungen der irritativen Wirkung des Dithranols mittesl Kapillarresistenzmessung. Z. Hautkr. 64:34.
69. Lawrence, C. M., and S. Shuster. 1985. Mechanism of anthralin inflammation. I. Dissociation of response to clobetasol and indomethacin. Br. J. Dermatol. 113: 107.